Xeris Biopharma Holdings Inc (XERS)
NASDAQ
Quarter End | 9 2022 | 12 2022 | 3 2023 | 6 2023 | 9 2023 | 12 2023 | 3 2024 | 6 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | ||||||
総売上 | 29.73M | 33.14M | 33.2M | 38.01M | 48.32M | 44.39M | 40.64M | 48.07M |
営業利益 | -18.78M | -15.17M | -13.28M | -15.98M | -4.91M | -9.84M | -14.25M | -8.19M |
税引前収入 | -22.17M | -13.27M | -16.83M | -20.52M | -12.53M | -13.63M | -18.67M | -14.26M |
純利益 | -21.83M | -12.93M | -16.83M | -19.84M | -12.19M | -13.39M | -18.98M | -15.01M |
優先配当 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
基本的1株当たり利益 (EPS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBIT | -18.66M | -10.76M | -11.92M | -15.2M | -3.98M | -7.71M | -13.57M | -7.59M |
EBITDA | -15.71M | -12.09M | -10.2M | -12.88M | -1.81M | -6.78M | -11.21M | -5.2M |
年末 2023年12月31日 | 2021 | 2022 | 2023 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
総売上 | 49.59M | 110.25M | 163.91M |
営業利益 | -115.16M | -81.94M | -44.01M |
税引前収入 | -122.73M | -96.08M | -63.5M |
純利益 | -122.73M | -94.66M | -62.26M |
優先配当 | 0 | 0 | 0 |
基本的1株当たり利益 (EPS) | -0.983 | -0.695 | -0.451 |
EBIT | -115.16M | -85.1M | -38.81M |
EBITDA | -113.28M | -69.7M | -31.68M |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約